Portal de Periódicos da CAPES

CHANGES IN CYCLIN DEPENDENT KINASE INHIBITORS p21 AND p27 DURING THE CASTRATION INDUCED REGRESSION OF THE CWR22 MODEL OF PROSTATIC ADENOCARCINOMA

1999; Lippincott Williams & Wilkins; Volume: 161; Issue: 3 Linguagem: Inglês

10.1016/s0022-5347(01)61826-3

1527-3792

Russell B. Myers, Denise K. Oelschlager, Patricia N. Coan, Andra R. Frost, Heidi L. Weiss, Upender Manne, Thomas G. Pretlow, William E. Grizzle,

Sarcoma Diagnosis and Treatment

No AccessJournal of UrologyInvestigative Urology1 Mar 1999CHANGES IN CYCLIN DEPENDENT KINASE INHIBITORS p21 AND p27 DURING THE CASTRATION INDUCED REGRESSION OF THE CWR22 MODEL OF PROSTATIC ADENOCARCINOMA RUSSELL B. MYERS, DENISE K. OELSCHLAGER, PATRICIA N. COAN, ANDRA R. FROST, HEIDI L. WEISS, UPENDER MANNE, THOMAS G. PRETLOW, and WILLIAM E. GRIZZLE RUSSELL B. MYERSRUSSELL B. MYERS , DENISE K. OELSCHLAGERDENISE K. OELSCHLAGER , PATRICIA N. COANPATRICIA N. COAN , ANDRA R. FROSTANDRA R. FROST , HEIDI L. WEISSHEIDI L. WEISS , UPENDER MANNEUPENDER MANNE , THOMAS G. PRETLOWTHOMAS G. PRETLOW , and WILLIAM E. GRIZZLEWILLIAM E. GRIZZLE View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)61826-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The expression of the cyclin dependent kinase inhibitors p21 and p27 was examined in prostatic adenocarcinomas following castration. Materials and Methods: Male nude mice inoculated with the androgen dependent human prostatic tumor CWR22 were castrated when the tumors reached a volume of 0.8 to 1.1 cm.3 and were sacrificed at 3, 7, 21, 28 and 42 days post-castration. An additional group of mice received a subcutaneous testosterone pellet at 21 days post-castration and was sacrificed at 28 days post-castration. The expression of the Ki-67 antigen, p21 and p27 was examined by immunohistochemistry. Results: The mitotic rate as well as the number of Ki-67 antigen positive cells decreased to 3% of intact control values by 7 days post-castration and were less than 0.01% of intact control values at 21, 28 and 42 days post-castration. The percentage of p21 expressing cells decreased from 15 +/− 2% in intact controls to less than 1% by 42 days post-castration. In contrast, the percentage of cells that expressed p27 increased from 25 +/− 3% in intact controls to 51 +/− 8% at 3 days post-castration and to 80 to 95% at days, 7, 21, 28 and 42 days post-castration. Testosterone treatment from 21 to 28 days post-castration resulted in an increase in Ki-67 antigen positive cells to 200% of intact controls and a concomitant reduction in p27 expressing cells to about 50% of intact controls. Castration-induced changes in p27 expression were not observed in the CWR22R tumor, a transplantable relapsed derivative of the CWR22 tumor. Conclusion: These findings suggest that p27 expression is regulated negatively by androgens and that increased expression of p27 in CWR22 xenografts may be involved in the suppression of proliferation following castration. References 1 : Studies on prostate cancer. I. The effect of castration, of estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res.1941; 1: 293. Google Scholar 2 : Hormonal therapy for prostate cancer. In: . Philadelphia: W. B. Saunders1993: 347. Google Scholar 3 : Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res.1990; 50: 3748. Google Scholar 4 : Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J. Urol.1996; 155: 213. Link, Google Scholar 5 : Hormones. In: . Boston, MA: CRC Press1991: 216. Google Scholar 6 : CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res.1994; 54: 6049. Google Scholar 7 : The effects of estroneprogesterone treatment on cell proliferation kinetics of hormone dependent GR mouse mammary tumors. Cancer Res.1975; 35: 3698. Google Scholar 8 : Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. Natl. Cancer Inst.1994; 86: 1140. Google Scholar 9 : A stepwise rejective multiple test procedure based on a modified Bonferroni test. Biometrika1988; 75: 383. Google Scholar 10 : Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J. Steroid Biochem. Mol. Biol.1996; 58: 139. Google Scholar 11 : A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res.1997; 57: 1585. Google Scholar 12 : CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res.1996; 56: 3042. Google Scholar 13 : CdK inhibitors: on the threshold of checkpoints and development. Current Opin. Cell Biol.1994; 6: 847. Google Scholar 14 : Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. Adv. Cancer Res.1997; 71: 165. Google Scholar 15 : p27Kip-1, a cyclin-CdK inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Develop.1994; 8: 9. Google Scholar 16 : Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF alpha receptor. J. Clin. Endocrinol. Metab.1993; 77: 1472. Google Scholar 17 : Expression of transforming growth factor-beta in the rat ventral prostate during castration induced programmed cell death. Mol. Endocrinol.1989; 3: 1515. Google Scholar 18 : Regulation of prostatic growth and function by peptide growth factors. Prostate1996; 28: 392. Crossref, Medline, Google Scholar 19 : Regulation of androgen-dependent prostatic cancer cell growth: Androgen regulation of CDK2, CDK4 and CKI p16 genes. Cancer Res.1997; 57: 4511. Google Scholar 20 : Increased proteasomore-dependent degradation of the cyclin dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med.1997; 3: 231. Google Scholar 21 : Translational control of p27Kip-1 accumulation during the cell cycle. Science (Washington, DC)1996; 271: 1861. Google Scholar 22 : Expression of G1 cyclins, cyclin dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ.1998; 7: 1571. Google Scholar 23 : Loss of cyclin-dependent kinase inhibitor p27Kip-1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res.1998; 58: 542. Google Scholar 24 : Interleukin-2-mediated elimination of the p27Kip-1 cyclin-dependent kinase inhibitor presented by rappamycin. Nature1994; 372: 570. Google Scholar From the Departments of Pathology, Comparative Medicine, UAB Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, and the Department of Pathology, Case Western Reserve University, Cleveland, OhioRequests for reprints: Department of Pathology, University of Alabama at Birmingham, University Station, Birmingham, AL 35294-0007.Supported in part by American Institute for Cancer Research Grant #97A154-REV.© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byMYERS R, OELSCHLAGER D, WEISS H, FROST A and GRIZZLE W (2018) FATTY ACID SYNTHASE: AN EARLY MOLECULAR MARKER OF PROGRESSION OF PROSTATIC ADENOCARCINOMA TO ANDROGEN INDEPENDENCEJournal of Urology, VOL. 165, NO. 3, (1027-1032), Online publication date: 1-Mar-2001. Volume 161Issue 3March 1999Page: 945-949 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.Metrics Author Information RUSSELL B. MYERS More articles by this author DENISE K. OELSCHLAGER More articles by this author PATRICIA N. COAN More articles by this author ANDRA R. FROST More articles by this author HEIDI L. WEISS More articles by this author UPENDER MANNE More articles by this author THOMAS G. PRETLOW More articles by this author WILLIAM E. GRIZZLE More articles by this author Expand All Advertisement PDF downloadLoading ...